Thapsigargin
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Unknown
- Developer LC Chemical Corporation; Merck & Co; Nonindustrial source; Unknown
- Class Anti-ischaemics; Antiarrhythmics; Cardiotonics; Lactones; Sesquiterpenes; Small molecules
- Mechanism of Action Calcium channel antagonists; Calcium-transporting ATPase inhibitors; JNK mitogen-activated protein kinase modulators; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias; Cancer; Heart failure; Ischaemic heart disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Singapore
- 19 Nov 2009 Preclinical trials in Cancer in Singapore (unspecified route)
- 19 Nov 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)